Suppr超能文献

复发性颅内脑膜瘤再手术的益处。

Benefits of re-do surgery for recurrent intracranial meningiomas.

机构信息

Department of Neurosurgery, University Hospital of Angers, Angers, France.

Department of Clinical Neurosciences, Division of Neurosurgery, Geneva University Hospitals, Geneva, Switzerland.

出版信息

Sci Rep. 2020 Jan 15;10(1):303. doi: 10.1038/s41598-019-57254-5.

Abstract

Meningiomas are the most common intracranial extra-axial tumor. While the literature is abundant on the therapeutic management of meningioma recurrence after the initial surgery, the natural history of repeated recurrences is poorly described, as well as and their respective management. A partly retrospective, partly prospective review was conducted in a Norwegian cohort of 1469 consecutive cases of meningioma surgically treated, totaling 11 414 patient-years of follow-up. 114 recurrences (7.7%) were treated surgically with a risk a surgical retreatment of 1% per patient-year of follow-up. 36 patients were operated on 3 times or more. The time-to-retreatment (TTR) decreased significantly and steadily between surgeries, from 4.3 ± 4 years after the first surgery to 2.4 ± 2.9 years after the third surgery. The primary driver for recurrence was the WHO grade (OR 7.13 [4.40;11.55], p < 0.001 for the first recurrence and OR 4.13 [1.49;12.15], p 0.008 for the second), the second predictive factor being a skull base location (OR 2.76 [1.95;3.99] p < 0.001 and OR 0.24 [0.09;0.65], p0.006 respectively). The rates of postoperative hematomas and infections were not influenced by the number of surgeries, whereas the rate of postoperative neurological worsening increased from 3.9% to 16.6% and 13.9%, respectively, after the first, second, and third surgeries. We observed that the TTR decreased significantly between surgeries in patients requiring repeated resections, indicating that surgical treatment of recurrences does not reset the clock but is indeed a "race against time". This should be considered when assessing the benefit-to-risk ratio of patients undergoing repeated surgeries for a recurrent meningioma.

摘要

脑膜瘤是最常见的颅内外轴肿瘤。尽管文献中大量描述了初次手术后脑膜瘤复发的治疗管理,但对多次复发的自然史及其各自的管理描述甚少。对挪威 1469 例连续接受手术治疗的脑膜瘤患者进行了部分回顾性、部分前瞻性回顾,共随访 11414 患者年。114 例(7.7%)复发患者接受手术治疗,每例患者每年的手术再治疗风险为 1%。36 例患者接受了 3 次或更多次手术。两次手术之间的再治疗时间(TTR)显著且稳定地缩短,从第一次手术后的 4.3±4 年缩短至第三次手术后的 2.4±2.9 年。复发的主要驱动因素是世界卫生组织(WHO)分级(第一次复发的 OR 为 7.13[4.40;11.55],第二次复发的 OR 为 4.13[1.49;12.15],p<0.001),第二个预测因素是颅底位置(OR 为 2.76[1.95;3.99],p<0.001 和 OR 为 0.24[0.09;0.65],p0.006)。手术次数并不影响术后血肿和感染的发生率,而术后神经恶化的发生率则从第一次、第二次和第三次手术分别从 3.9%增加至 16.6%和 13.9%。我们观察到,在需要重复切除的患者中,两次手术之间的 TTR 显著缩短,这表明手术治疗复发并不能重置时钟,而是确实是一场“与时间赛跑”。在评估反复手术治疗复发性脑膜瘤患者的获益-风险比时,应考虑这一点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ed1/6962359/bdee1d0bb40b/41598_2019_57254_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验